[go: up one dir, main page]

DK1032662T3 - Fremgangsmåder og sammensætninger til immunmodulation - Google Patents

Fremgangsmåder og sammensætninger til immunmodulation

Info

Publication number
DK1032662T3
DK1032662T3 DK98952476T DK98952476T DK1032662T3 DK 1032662 T3 DK1032662 T3 DK 1032662T3 DK 98952476 T DK98952476 T DK 98952476T DK 98952476 T DK98952476 T DK 98952476T DK 1032662 T3 DK1032662 T3 DK 1032662T3
Authority
DK
Denmark
Prior art keywords
methods
compositions
protein
useful
disclosed
Prior art date
Application number
DK98952476T
Other languages
Danish (da)
English (en)
Inventor
Reginald M Gorczynski
David A Clark
Original Assignee
Trillium Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22058127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1032662(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trillium Therapeutics Inc filed Critical Trillium Therapeutics Inc
Application granted granted Critical
Publication of DK1032662T3 publication Critical patent/DK1032662T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
DK98952476T 1997-11-07 1998-11-06 Fremgangsmåder og sammensætninger til immunmodulation DK1032662T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6476497P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
DK1032662T3 true DK1032662T3 (da) 2006-07-03

Family

ID=22058127

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98952476T DK1032662T3 (da) 1997-11-07 1998-11-06 Fremgangsmåder og sammensætninger til immunmodulation

Country Status (12)

Country Link
US (6) US6338851B1 (fr)
EP (1) EP1032662B1 (fr)
JP (2) JP4584447B2 (fr)
AT (1) ATE319825T1 (fr)
AU (1) AU748587B2 (fr)
CA (1) CA2308765C (fr)
CY (1) CY1105364T1 (fr)
DE (1) DE69833779T2 (fr)
DK (1) DK1032662T3 (fr)
ES (1) ES2260852T3 (fr)
PT (1) PT1032662E (fr)
WO (1) WO1999024565A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833779T2 (de) 1997-11-07 2006-11-30 Trillium Therapeutics Inc., Toronto Verfahren und zusammensetzungen zur immunomodulation
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
WO2001008700A1 (fr) * 1999-07-28 2001-02-08 Genetics Institute, Inc. Prevention d'avortements d'origine immunologique par l'inhibition de signaux de costimulation
US7291330B2 (en) 2000-03-17 2007-11-06 Trillium Therapeutics Inc. MD-1 inhibitors as immune suppressants
US20030186384A1 (en) * 2000-04-22 2003-10-02 Stefan Barth Apoptotic agents
CA2417874C (fr) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Utilisation des inhibiteurs ox-2 pour le traitement du cancer
AUPR069500A0 (en) 2000-10-11 2000-11-09 Coster, Douglas John Tissue modification
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (fr) 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Lignee cellulaire de la leucemie lymphoide chronique
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
US7285631B2 (en) 2001-08-10 2007-10-23 Serono Genetics Institute S.A. Human cDNAs and proteins and uses thereof
EP2316485A1 (fr) * 2001-10-12 2011-05-04 Schering Corporation Composition pour soins personnels
US7196243B2 (en) 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
AU2003299823A1 (en) * 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
EP2604703B1 (fr) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Procédés permettant d'évaluer la survie d'un greffon chez un destinataire d'une transplantation d'organe solide
GB0506721D0 (en) * 2005-04-01 2005-05-11 Univ Glasgow Soluble immunoregulatory factor
AU2007207764B2 (en) 2006-01-12 2012-06-07 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
WO2008085963A1 (fr) * 2007-01-05 2008-07-17 University Of Florida Research Foundation, Inc. Matériaux et procédés pour la détection, la prévention et le traitement d'une maladie auto-immune
EP2178561A1 (fr) * 2007-07-25 2010-04-28 Alexion Pharmaceuticals, Inc. Anticorps dirigés contre cd200 et leurs utilisations dans l'inhibition de réponses immunitaires
BRPI0814645A2 (pt) 2007-07-25 2015-01-27 Alexion Pharma Inc Métodos e composições para tratar de doença autoimune.
ES2492498T3 (es) * 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
EP2507630B1 (fr) 2009-12-02 2017-01-25 The Board of Trustees of The Leland Stanford Junior University Biomarqueurs pour déterminer un xénotype tolérant à l'allogreffe
IN2012DN06309A (fr) 2010-01-11 2015-09-25 Alexion Pharma Inc
KR20130036192A (ko) 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
WO2011113027A2 (fr) 2010-03-12 2011-09-15 Synageva Biopharma Corp Protéines de fusion npp1
WO2012125182A1 (fr) 2011-03-11 2012-09-20 Synageva Biopharma Corp Protéines hybrides npp1
EP2803735B1 (fr) 2010-03-25 2020-03-25 The Board of Trustees of the Leland Stanford Junior University Biomarqueurs de protéines et de gènes pour le rejet d'organes transplantés
EP3626739A1 (fr) 2011-06-24 2020-03-25 Stephen D. Gillies Protéines de fusion d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
KR102833432B1 (ko) 2014-12-19 2025-07-14 이노자임 파마, 인코포레이티드 조직 석회화의 치료 방법
WO2017079335A1 (fr) 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Inhibiteurs de cd200 et leurs méthodes d'utilisation
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
WO2019067499A1 (fr) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Signature de biomarqueur pour la prédiction d'une réponse tumorale vis-à-vis d'une thérapie anti-cd200
WO2019067502A1 (fr) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Méthodes d'amélioration de la fonction cardio-vasculaire et de traitement d'une maladie cardio-vasculaire à l'aide d'une ecto-nucléotide pyrophosphatase/phosphodiestérase recombinante
WO2019084682A1 (fr) 2017-10-30 2019-05-09 Mcmaster University Méthodes pour le diagnostic et le traitement de l'endométriose
WO2019126133A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Formulations liquides d'anticorps anti-cd200
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations
US12414983B2 (en) 2019-01-14 2025-09-16 Regents Of The University Of Minnesota CD200AR ligands for cancer immunotherapy
GB202303291D0 (en) * 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123001T5 (es) * 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
GB9505653D0 (en) * 1995-03-21 1995-05-10 Shober Wharton Method of pest control
WO1997021450A1 (fr) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Molecule costimulante ox-2
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
DE69833779T2 (de) * 1997-11-07 2006-11-30 Trillium Therapeutics Inc., Toronto Verfahren und zusammensetzungen zur immunomodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
US7291330B2 (en) 2000-03-17 2007-11-06 Trillium Therapeutics Inc. MD-1 inhibitors as immune suppressants
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
US7196243B2 (en) * 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery

Also Published As

Publication number Publication date
US6749854B2 (en) 2004-06-15
CA2308765C (fr) 2010-10-12
US20020103151A1 (en) 2002-08-01
JP2001522867A (ja) 2001-11-20
CA2308765A1 (fr) 1999-05-20
CY1105364T1 (el) 2010-03-03
JP2010155846A (ja) 2010-07-15
ES2260852T3 (es) 2006-11-01
ATE319825T1 (de) 2006-03-15
US6652858B2 (en) 2003-11-25
US7902151B2 (en) 2011-03-08
EP1032662B1 (fr) 2006-03-08
HK1030625A1 (en) 2001-05-11
US20020151485A1 (en) 2002-10-17
DE69833779T2 (de) 2006-11-30
US6338851B1 (en) 2002-01-15
PT1032662E (pt) 2006-07-31
WO1999024565A1 (fr) 1999-05-20
US20020086011A1 (en) 2002-07-04
DE69833779D1 (de) 2006-05-04
US20090232825A1 (en) 2009-09-17
JP4584447B2 (ja) 2010-11-24
AU1017399A (en) 1999-05-31
AU748587B2 (en) 2002-06-06
US6984625B2 (en) 2006-01-10
EP1032662A1 (fr) 2000-09-06
US20110206668A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
DK1032662T3 (da) Fremgangsmåder og sammensætninger til immunmodulation
PL328858A1 (en) Immunogenous peptides
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE69840025D1 (de) Assoziierter antworten
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
WO2001068697A3 (fr) Techniques et compositions relatifs à l'immunorégulation
AU8497701A (en) Claudin polypeptides
DK1017667T3 (da) 2-amino-6-methyl-7-acetyltetralin og farmaceutiske præparater til forebyggelse og terapeutisk behandling af inflammatoriske og/eller autoimmune patalogier
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DK0977871T3 (da) Neurotrypsin
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
AU2003208197A8 (en) Use of soluble fgl2 as an immunosuppressant
ITBZ950045A0 (it) Gioiello e procedimento per la realizzazione dello stesso.
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
WO2001062792A3 (fr) Traitement et prevision du cancer
TW200635953A (en) Specific binding agents of human angiopoietin-2
MX9705119A (es) Interferona modificada quimicamente.
ITMI932544A0 (it) Composizioni farmaceutiche e/o dermocosmetologiche e cosmetiche contenenti colostro bovino.
IT238894Y1 (it) Combinazione di elementi facenti funzioni di lenti con partiornamentale e/o preziose, su prodotti di oreficeria e/o bigiotteria
ZA988293B (en) Compositions and methods for the treatment of tumor.
IT8619772A0 (it) Acesamato di 1-benzil-3-(3-dimetilaminopropossi)-1h-indazolo e composizioni farmaceutiche che lo contengono.